Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial

• Published in: Archives of neurology (Chicago) Vol. 81; no. 6; p. 582
• Main Authors: Wagemann, Olivia, Liu, Haiyan, Wang, Guoqiao, Shi, Xinyu, Bittner, Tobias, Scelsi, Marzia A, Farlow, Martin R, Clifford, David B, Supnet-Bell, Charlene, Santacruz, Anna M, Aschenbrenner, Andrew J, Hassenstab, Jason J, Benzinger, Tammie L S, Gordon, Brian A, Coalier, Kelley A, Cruchaga, Carlos, Ibanez, Laura, Perrin, Richard J, Xiong, Chengjie, Li, Yan, Morris, John C, Lah, James J, Berman, Sarah B, Roberson, Erik D, van Dyck, Christopher H, Galasko, Douglas, Gauthier, Serge, Hsiung, Ging-Yuek R, Brooks, William S, Pariente, Jérémie, Mummery, Catherine J, Day, Gregory S, Ringman, John M, Mendez, Patricio Chrem, St George-Hyslop, Peter, Fox, Nick C, Suzuki, Kazushi, Okhravi, Hamid R, Chhatwal, Jasmeer, Levin, Johannes, Jucker, Mathias, Sims, John R, Holdridge, Karen C, Proctor, Nicholas K, Yaari, Roy, Andersen, Scott W, Mancini, Michele, Llibre-Guerra, Jorge, Bateman, Randall J, McDade, Eric
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.06.2024
• Subjects: Adult; Aged; Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Biomarkers; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Chitinase; Chitinase-3-Like Protein 1 - blood; Chitinase-3-Like Protein 1 - cerebrospinal fluid; Clinical trials; Correlation analysis; Dosage; Double-Blind Method; Female; Glial fibrillary acidic protein; Humans; Inflammation; Male; Medical imaging; Middle Aged; Myeloid cells; Neurodegeneration; Neurodegenerative diseases; Neurofilament Proteins - blood; Neurofilament Proteins - cerebrospinal fluid; Neurogranin; Neuroimaging; Neuronal-glial interactions; Peptides; Placebos; Plasma; Plasma levels; Positron emission; Positron emission tomography; Proteins

Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). To investigate longitudinal biomarker changes of synaptic dysfunctio...